2015

HAI/WHO Pharmaceutical Promotion Manual Still Key to Combating Promotion around the World

It’s Time Everyone Knows about Price Inequities in Insulin

HAI Holds Workshops on EU Medicines Policy & Access to Medicines in Eastern Europe

HAI urges MEPs to support key amendments to TTIP resolution

The EU-US Trade Deal Could Leave Europeans Sick

World Health Assembly Executive Board 136: YP-CDN, NWIA and HAI intervention on the WHO’s internship programme

HAI Launches Innovative Global Study to Improve Access to Insulin

In memory of our Foundation Board Chair, Atze Sybrandy

2014

Student Stop AIDS National Gathering an inspiring start to Access to Medicines Week

Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry

Democracy violation: European Commission rejects citizens’ initiative to stop TTIP and CETA

School's IN for summer: HAI staff and interns inspired by Utrecht University's course on pharmaceutical policy analysis

BMJ statins debate about scientific independence, not rigour

Progress on access to medicines at WHA67, but WHO funding sorely needed

World Health Assembly 67: HAI and KEI intervention on the Consultative Expert Working Group on Research and Development

World Health Assembly 67: HAI intervention on access to essential medicines

World Health Assembly 67: HAI intervention on the WHO's framework of engagement with non-state actors

Tamiflu review shows desperate need for full clinical trials data transparency

Governments must ensure Big Pharma’s expansion in Africa doesn’t impede generics supply

New materials help assess medicines policies and interventions

A new (and improved) model to regulate pharmaceutical promotion

Enhancing accountability in the medicines market: The Medicines Transparency Alliance

Bayer CEO's callous comments highlight failure of current biomedical innovation model

2013

When politicians go to the movies

2011

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs